Suppr超能文献

2017 年缅甸甲型 H1N1 流感的全基因组序列分析及首例奥司他韦耐药株。

Epidemic of influenza A(H1N1)pdm09 analyzed by full genome sequences and the first case of oseltamivir-resistant strain in Myanmar 2017.

机构信息

Infectious Diseases Research Center of Niigata University in Myanmar (IDRC), Yangon, Yangon Region, Myanmar.

Division of International Health, Graduate School of Medical and Dental Sciences, Niigata University, Niigata, Niigata, Japan.

出版信息

PLoS One. 2020 Mar 4;15(3):e0229601. doi: 10.1371/journal.pone.0229601. eCollection 2020.

Abstract

A community outbreak of human influenza A(H1N1)pdm09 virus strains was observed in Myanmar in 2017. We investigated the circulation patterns, antigenicity, and drug resistance of 2017 influenza A(H1N1)pdm09 viruses from Myanmar and characterized the full genome of influenza virus strains in Myanmar from in-patients and out-patients to assess the pathogenicity of the viruses. Nasopharyngeal swabs were collected from out-patients and in-patients with acute respiratory tract infections in Yangon and Pyinmana City in Myanmar during January-December 2017. A total of 215 out-patients and 18 in-patients infected with A(H1N1)pdm09 were detected by virus isolation and real-time RT-PCR. Among the positive patients, 90.6% were less than 14 years old. Hemagglutination inhibition (HI) antibody titers against A(H1N1)pdm09 viruses in Myanmar were similar to the recommended Japanese influenza vaccine strain for 2017-2018 seasons (A/Singapore/GP1908/2015) and WHO recommended 2017 southern hemisphere vaccine component (A/Michigan/45/2015). Phylogenetic analysis of the hemagglutinin sequence showed that the Myanmar strains belonged to the genetic subclade 6B.1, possessing mutations of S162N and S164T at potential antigenic sites. However, the amino acid mutation at position 222, which may enhance the severity of disease and mortality, was not found. One case with no prior history of oseltamivir treatment possessed H275Y mutated virus in neuraminidase (NA), which confers resistance to oseltamivir and peramivir with elevated IC50 values. The full genome sequence of Myanmar strains showed no difference between samples from in-patients and out-patients, suggesting no additional viral mutations associated with patient severity. Several amino acid changes were observed in PB2, PB1, and M2 of Myanmar strains when compared to the vaccine strain and other Asian strains. However, no mutations associated with pathogenicity were found in the Myanmar strains, suggesting that viral factors cannot explain the underlying reasons of the massive outbreak in Myanmar. This study reported the first detection of an oseltamivir-resistant influenza virus in Myanmar, highlighting the importance of continuous antiviral monitoring and genetic characterization of the influenza virus in Myanmar.

摘要

2017 年,缅甸出现了人类甲型流感 A(H1N1)pdm09 病毒株的社区暴发。我们调查了来自缅甸的 2017 年甲型流感 A(H1N1)pdm09 病毒的循环模式、抗原性和耐药性,并对来自住院和门诊患者的流感病毒株进行了全基因组特征分析,以评估病毒的致病性。2017 年 1 月至 12 月,从仰光和 Pyinmana 市急性呼吸道感染的门诊和住院患者中采集了鼻咽拭子。通过病毒分离和实时 RT-PCR 共检测到 215 例门诊和 18 例住院的 A(H1N1)pdm09 感染患者。阳性患者中,90.6%年龄小于 14 岁。来自缅甸的 A(H1N1)pdm09 病毒的血凝抑制(HI)抗体滴度与推荐用于 2017-2018 季节的日本流感疫苗株(A/Singapore/GP1908/2015)和世界卫生组织(WHO)推荐的 2017 年南半球疫苗成分(A/Michigan/45/2015)相似。血凝素序列的系统发育分析表明,缅甸株属于遗传亚分支 6B.1,在潜在抗原位点存在 S162N 和 S164T 的突变。然而,未发现可能增强疾病严重程度和死亡率的位置 222 上的氨基酸突变。一个没有奥司他韦治疗史的病例在神经氨酸酶(NA)中具有 H275Y 突变病毒,这会导致奥司他韦和帕拉米韦的耐药性,并使 IC50 值升高。缅甸株的全基因组序列显示,住院和门诊患者样本之间没有差异,表明与患者严重程度相关的病毒突变没有增加。与疫苗株和其他亚洲株相比,缅甸株的 PB2、PB1 和 M2 中观察到几个氨基酸变化。然而,在缅甸株中没有发现与致病性相关的突变,这表明病毒因素不能解释缅甸大规模暴发的根本原因。本研究首次报道了缅甸奥司他韦耐药流感病毒的检测,强调了在缅甸持续进行抗病毒监测和流感病毒遗传特征分析的重要性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ff77/7055873/7ba848a82012/pone.0229601.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验